Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ligand Pharm
(NQ:
LGND
)
106.39
+0.50 (+0.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ligand Pharm
< Previous
1
2
3
4
5
6
Next >
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...
Via
Benzinga
Ligand to Report Fourth Quarter Financial Results on February 17
February 09, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
December 22, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand and GSK Expand Global Collaboration and License Agreement
December 21, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Meme Stock Breakdown
December 14, 2021
There have been plenty of market happenings and themes in 2021 but perhaps one of the more intriguing ones was the recurring bouts of meme stock mania.
Via
Talk Markets
Ligand Pharmaceuticals Sees RS Rating Rise To 92
November 11, 2021
A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.
Via
Investor's Business Daily
Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company
November 10, 2021
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced plans to split into two separate publicly traded companies. One company will feature the OmniAb...
Via
Benzinga
Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earnings Call Transcript
November 10, 2021
LGND earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Recap: Ligand Pharmaceuticals Q3 Earnings
November 09, 2021
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:01 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Ligand Reports Third Quarter 2021 Financial Results
November 09, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
November 09, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
Ligand to Report Third Quarter Financial Results on November 9, 2021
October 26, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
Ligand Outlicenses BEPro Tech To Develop Oral COVID-19 Antivirals
October 21, 2021
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has signed a collaboration agreement with Double-Crane Pharmaceutical Co Ltd (CRDC). The agreement grants...
Via
Benzinga
Exposures
COVID-19
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
October 21, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Stock Shows Rising Price Performance
September 22, 2021
A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance.
Via
Investor's Business Daily
Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating
September 20, 2021
Ligand Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 71 to 82.
Via
Investor's Business Daily
Why Digital Turbine's Stock Is Trading Higher Today
August 31, 2021
Digital Turbine Inc (NASDAQ: APPS) is trading higher Tuesday after it was announced the company is set to join the S&P MidCap 400. Digital Turbine will replace ...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Digital Turbine Added To S&P MidCap 400 Index
August 31, 2021
Media and mobile communications company Digital Turbine Inc (NASDAQ:
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
August 31, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
August 30, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
August 16, 2021
From
Ligand Pharmaceuticals
Via
Business Wire
What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months
August 12, 2021
Stock transactions by members of the U.S. Congress and their spouses have been a hot topic over the last several years. A transaction disclosed late Wednesday is drawing heavy...
Via
Benzinga
Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript
July 30, 2021
LGND earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Ligand Reports Second Quarter 2021 Financial Results
July 29, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
July 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
July 21, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
July 19, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.